oral FGFR inhibitor - Astellas Pharma Inc.

oral FGFR inhibitor

Ph. I candidate for solid tumors

opt. from previously disclosed lead

Bioorg. Med. Chem.

Astellas Pharma Inc.

ontext. ASP5878 (Astellas Pharma Inc.) is an oral pan-FGFR inhibitor. The four FGFRs have emerged as attractive targets for cancer in recent years, and we’ve covered several recently. FGFR3…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.